December 2015

Physiomics plc is pleased to announce that it has signed a new contract with another new speciality pharma customer, to perform PK/PD modelling analysis for a novel combination and translate the results into the clinic. This will be the Company's first project related to drugs treating pain    ...

Read More

Chairman's Statement  Summary of Results in the year ended 30 June 2015 •    The turnover of the Company was £235,486 (2014: £267,903). •    The operating loss reduced to £414,755 (2014: £465,265). •    On 30 June 2015 the surplus of shareholders' funds was £325,617 (2014: £136,487). This year, Physiomics extended its product range and made a key commercial breakthrough, signing its first long term Virtual Tumour Clinical deal with a large pharmaceutical company. In summary...

Read More

Physiomics is pleased to provide an update on its strategic direction. For some time the Company has been pursuing M&A targets, in particular oncology therapeutics companies that could benefit from the application of Virtual Tumour and other PYC modelling tools. Physiomics has now identified a number of potential targets, including one in particular where the synergy with our modelling skills is strong....

Read More

Physiomics plc is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford. He is an eminent clinician with highly relevant clinical experience. Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research...

Read More

Physiomics will present a half-day workshop on “Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science”, ahead of the 2015 PAGE meeting. This workshop will review the preclinical Virtual Tumour model used to predict optimal doses and schedules of combination therapy. We will provide an overview regarding the recent extension of the current model to include immunotherapy and clinical translational. This will then be...

Read More

Dr Hugues Dolgos, Global Head, Quantitative Pharmacology & Drug Disposition, Merck Serono, is presenting at the Quantitative Systems Pharmacology meeting today in Basel, Switzerland. His presentation, entitled “Transforming Modeling & Simulation at Merck-Serono to Implement the Translational Medicine Strategy”, will include a section on Physiomics technology. ...

Read More

Physiomics plc is pleased to announce that it is participating in the American Association for Cancer Research Annual Meeting 2015, taking place at the Pennsylvania Convention Center, Philadelphia, Pennsylvania on 18-22 April 2015. Dr Frances Brightman will present on the application of the Virtual Tumour platform to predict agents targeting the PD-1/PD-L1 axis in combination with radiotherapy. ...

Read More

Physiomics plc is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono, the biopharmaceutical division of Merck, Germany. Revenue from the contract will fall in the 2014/2015 and 2015/2016 financial years and is in the region of the total value of all of Physiomics 2013/2014 sales. As such it...

Read More